May 24 / 2019
Sala Polivalente del Parc de Recerca UAB

A collaborative project was presented between the companies ABAC Therapeutics, Draconis Pharma and Isoquimenera for the in vivo evaluation of new molecules with antibacterial activity.

The phenomenon of antimicrobial resistance (AMR) describes the capacity of microorganisms such as bacteria, fungi, virus and parasites react against antimicrobial drugs, often by means of mutation, so that they are not inhibited and therefore can continue multiplying and spreading.
This give rise to resistant strains capable of withstanding the therapeutic effects of antibiotic, antiviral, antifungal and anthelmintic drugs, among others. This natural phenomenon has been accelerated by the systematic abuse of antimicrobial drugs, especially antibiotics, for the treatment of humans, animals and vegetables.
The global movement of people, food products, animals and plants makes it very easy for pathogens to circulate along simultaneous routes. 
The propagation of antimicrobial resistance potentially complicates the capacity to treat common infectious diseases and affects higher morbidity and mortality rates.


Núria Martí Ras


Director of Innovation at Biocat

Lluís Gómez

Scientific Director at Draconis Pharma

Toni Bermúdez

Test Facility Manager at Isoquimen